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Background: Clostridium difficile infection (CDI) has markedly risen and is associated with hypervirulent ribotype 027 outbreaks in 
North America and Europe since 2003. The aims of this study were to determine the prevalence of ribotype 027 among C. difficile 
isolates in Korea, to characterize the ribotype 027 isolates, and to determine the clinical severity of CDI in patients infected with 
these isolates.
Methods: A total of 1,251 isolates of C. difficile recovered from stool specimens of suspected CDI patients at two tertiary-care hos-
pitals and one commercial laboratory between 2002 and 2009.  Genes for toxin A (tcdA), toxin B (tcdB), and binary toxin (cdtA and 
cdtB) were detected by PCR. Mutation in the tcdC gene was detected by sequencing after PCR amplification. For molecular geno-
typing, we performed PCR-ribotyping, pulsed-field gel electrophoresis (PFGE), and multilocus variable-number tandem-repeat 
analysis (MLVA). Minimum inhibitory concentrations of moxifloxacin were determined using Etest strips (AB bioMérieux, Sweden). 
Results: We identified 7 isolates as ribotype 027. These isolates had the same tcdC mutation as the epidemic strain, and 6 of them 
were resistant to moxifloxacin. The isolates were categorized into 3 different PFGE types and 7 different MLVA types. All the 7 cases 
had occurred sporadically. 
Conclusions: C. difficile ribotype 027 is uncommon, but it has emerged in Korea. The spread of this ribotype should be closely 
monitored in order to avoid an outbreak of CDI in Korea.
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INTRODUCTION
Severe Clostridium difficile infections (CDIs) associated 
with an emerging epidemic strain, PCR-ribotype 027, have 
increased in frequency and severity in the U.S., Canada, and 
the European countries since 2003 [1]. However, reports of 
ribotype 027 infections in East Asian countries remain rare 
[2]. One case each was reported from Japan [3] and Korea 
[4] in 2007 and 2009, respectively. A one-year surveillance 
study between 2007 and 2008 in Shanghai, China failed to 
detect any cases, although one case was reported in Hong 
Kong in 2009 [2]. These results may indicate the onset of 
spreading ribotype 027 infection in Asian countries. 
Ribotype 027 strain had toxin A, toxin B and binary toxin 
with deletion of toxin regulator gene (tcdC) [1]. According 
to a previous study, the use of moxifloxacin is associated 
with ribotype 027 outbreaks, and the isolates obtained in 
that study were resistant to levofloxacin and moxifloxacin 
[5]. A Korean isolate was resistant, whereas 1 Japanese iso-
late was susceptible to moxifloxacin [3, 4]; this indicated a 
need for further testing of Korean isolates. 
The aims of this study were to determine the prevalence of 
ribotype 027 among the stored C. difficile isolates, to charac-
terize the ribotype 027 isolates, and to evaluate the clinical 
severity of CDI in patients infected with these strains.
192     www.kjlm.org
Kim H, et al.  •  Emergence of C. difficile 027 in Korea
DOI 10.3343/kjlm.2011.31.3.191
KJLM
METHODS
1. Bacterial isolates and antimicrobial susceptibility testing
A total of 1,251 C. difficile isolates were recovered from 
stool specimens of suspected CDI patients at two tertiary-
care hospitals and one commercial laboratory between 2002 
and 2009. The commercial laboratory processed the stool 
specimens collected from hospitals and clinics without in-
house anaerobic microbiological testing facilities. C. difficile 
selective agar (CDSA; Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) was used to isolate C. difficile un-
der anaerobic incubation. The isolates were identified using 
conventional tests and the ATB 32A system (bioMerieux, 
Marcy l’Etoile, France). Minimum inhibitory concentrations 
(MICs) of moxifloxacin for ribotype 027 isolates were deter-
mined using Etest strips (AB bioMérieux, Solna, Sweden). 
2. Clinical characteristics of patients
We reviewed the patients’ medical records, and according 
to the criteria proposed by Zar et al. [6], patients with ≥2 
points were considered to have severe CDI. One point was 
given for each of the following criteria: age >60 yr, body 
temperature >38.3˚C, serum albumin <2.5 mg/dL, and pe-
ripheral white blood cell count >15,000/μL. Two points 
were given if there was endoscopic evidence of pseudo-
membranous colitis (PMC) or if the patient was admitted 
to the intensive care unit.
3. PCR assay for toxin genes
C. difficile toxin genes were detected by performing PCR as 
described in previous studies [7, 8]. Primer sequences used in 
this study are listed in Table 1. C. difficile VPI 10463 (A+ B+, 
CDT−), 3608/03 (A−B−, CDT−), SE844 (A+B+, CDT+), and 
1470 (A−B+, CDT−) were used as controls for the PCR as-
says. The obtained amplicons were commercially sequ-
enced (Macrogen, Seoul, Korea). The deduced amino acid 
sequences were compared to those of the strain VPI 10463.
4. PCR-ribotyping
PCR-ribotyping was performed according to a previously 
described method [9] with minor modification. We added 
10 µL of crude nucleic acid as template to a 50-µL PCR mix-
ture containing 10 mM Tris-HCl (pH 8.3) and 50 mM KCl 
(GeneAmp 1×PCR Buffer II; Applied Biosystems, Foster 
City, CA, USA), 4.0 mM MgCl2, 0.4 mM dNTP, 1.5 U Taq 
DNA polymerase (AmpliTaq Gold, Applied Biosystems), 
and 0.4 µM primers (CD1 and CD1445).
5. Pulsed-field gel electrophoresis and multilocus variable-
     number tandem-repeat analysis typing
Pulsed-field gel electrophoresis (PFGE) analysis was per-
formed by modified method of Alonso et al. [10]. In brief, 
we prepared plugs of chromosomal DNA from fresh colo-
nies cultured for 24 hr and treated them with high concen-
tration of proteinase K (75 U/mL). Thiourea was added to 
the gel and running buffer used for PFGE [11].
Multilocus variable-number tandem-repeat analysis (ML-
VA) was performed by PCR amplification and sequence 
analysis of 7 selected C. difficile repeat (CDR) loci; CDR4, 
CDR5, CDR9, CDR48, CDR49, CDR59, and CDR60. The 
primer sets used are listed in Table 1 [12]. The copy num-
bers of each of the 7 CDR loci were concatenated to gener-
ate an MLVA type for each isolate.
Table 1. Primers used in this study
Test Target Primer Oligonucleotide sequence (5´→3´) Reference
Toxin genes tcdA NK9 CCACCAGCTGCAGCCATA [7]
rep NK11 TGATGCTAATAATGAATCTAAAATGGTAAC
tcdB NK104 GTGTAGCAATGAAAGTCCAAGTTTACGC
NK105 CACTTAGCTCTTTGATTGCTGCACCT
cdtA cdtA pos TGAACCTGGAAAAGGTGATG
cdtA rev AGGATTATTTACTGGACCATTTG
cdtB cdtB pos CTTAATGCAAGTAAATACTGAG
cdtB rev AACGGATCTCTTGCTTCAGTC
PCR 16S-23S CD1 GCGCCCTTTGTAGCTTGACC [9]
  ribotyping rRNA CD1445 CTGGGGTGAAGTCGTAACAAGG
tcdC tcdC PaL15 TCTCTACAGCTATCCCTGGT [8] 
  mutation PaL16 AAAAATGAGGGTAACGAATTT
MLVA CDR4F ATTAATCATATCCTACAGAACACGA [12]
CDR4R TAAAACAAATGATATAAACTGAAAAG
CDR5F AATTTTAAGTTAACGTTTTTCTACAT
CDR5R AGCCATTTTTATCAATCCTTTCTAT
CDR9F TCTGGGATGTAACTAGCGACTTGT
CDR9R TCTGGGATGTAACTAGCGACTTGT
CDR48F AGGAGCTTTATATGGACATTCAGGTAG
CDR48R AATCTCTTTCAAACTCTTCAATCTCAAT
CDR49F A ACATATTTAGGCATTTTAGTC
CDR49R GAGTATTATTTATCATTTGTGGGTATTA
CDR59F GTAGAAGGGGCAAATAATGAG
CDR59R CCTTCTGGCTTCCTTGTA ATA
CDR60F GGTGCACATGCTGGTCCTG
CDR60R AACGCATTAAATTTCACTCCTCATAC
Abbreviations: MLVA, multilocus variable-number tandem-repeat analysis; CDR, Clos-
tridium difficile repeat.
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RESULTS
Of the 1,251 C. difficile isolates, 47 (3.8%) were PCR posi-
tive for the toxin A, toxin B, and binary toxin genes, and 7 
(0.6%) were identified as ribotype 027 by PCR-ribotyping. 
The first isolate to be identified as ribotype 027 was from a 
sample obtained in 2006, and the prevalence of ribotype 
027 was 0.6% in 2006 and 2007, 0.9% in 2008, and 1.0% in 
2009 (Table 2). 
All the ribotype 027 isolates had an 18-bp deletion from 
position 330 to 347 and a 1-bp deletion at position 117 in 
the tcdC gene sequence. We observed identical PFGE pat-
terns for 5 isolates (isolates 1, 4, 5, 6, and 7). However, the 
patterns for isolates 2 and 3 differed from those of the other 
isolates in 3 and 2 bands, respectively (Table 3, Fig. 1).
All the 7 isolates had different MLVA types. However, all 
the isolates had the same number of variable number tandem 
repeats (VNTRs) at the CDR5 and CDR59 loci (Table 3). 
The MIC of moxifloxacin was >32 μg/mL for 6 of the 7 
isolates and 0.5 μg/mL for the remaining 1 isolate (isolate 2).
Brief histories of patients infected with ribotype 027 are 
summarized in Table 4. The ages of the 7 patients (2 men 
and 5 women) were in the range of 25 to 88 yr, except a 
clinically-irrelevant 40-day-old infant with acute gastroen-
teritis. 
All patients had been hospitalized for some underlying 
diseases. Four patients had received anti-tuberculous medi-
cation 2-4 weeks before hospitalization. None of the pa-
Table 3. Molecular and phenotypic characteristics of the Clostridium difficile PCR-ribotype 027 
No. of Isolate Year of isolation Hospital* PFGE type
MLVA (N of VNTRs for each CDR locus) MIC of moxifloxacin 
(μg/mL)CD R 4 CD R 5 CD R 9 CD R 48 CD R 49 CD R 59 CD R 60
1 2006 Y I 20 3 14 9 12 1 12 >32
2 2007 S III 33 3 12 8 11 1 11 0.5
3 2008 K II 29 3 14 9 13 1 9 >32
4 2008 K I 20 3 15 9 12 1 10 >32
5 2008 G I 17 3 14 9 12 1 10 >32
6 2009 Y I 23 3 14 9 13 1 10 >32
7 2009 S I 25 3 16 10 12 1 9 >32
*Two hospitals, hospitals K and G, sent the samples to a commercial laboratory, and the samples were redirected to the S hospital in Seoul where the test was performed.
Abbreviations: PFGE, pulsed-field gel electrophoresis; MLVA, multilocus variable-number tandem-repeat analysis; VNTR, variable number tandem repeat; CDR, C. difficile repeat; 
MIC, minimum inhibitory concentration.
                        Lane             1          2          3         4          5         6           7        8         9
                        Patient                     3          1         4          5         2          6         7
                        PFGE            M         II           I           I          I          III          I          I        M
bp
400
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Fig. 1. Pulsed-field gel electrophoresis (PFGE) patterns of SmaI-digested ge-
nomic DNA obtained from the ribotype 027 isolates. Lanes 1 and 9 were 
loaded with a 50-kb ladder (molecular marker). The PFGE patterns for isolates 
2 and 3 differed in 5 bands. The remaining 5 isolates had identical patterns, 
and their pattern differed from that of isolates 2 and 3 in 3 and 2 bands, re-
spectively.
Table 2. Prevalence of binary toxin-producing Clostridium difficile and PCR- 
ribotype 027 
Year
N of isolates
Total
Binary toxin (+) Ribotype 027
S 
hospital
Y 
hospital
Commercial
Lab. N % N %
2002 179 ND ND 179  3 1.7 0 0.0
2003 107 ND ND 107  0 0.0 0 0.0
2004  53 ND ND  53  1 1.9 0 0.0
2005  40   2 ND  42  1 2.4 0 0.0
2006 155  19 ND 174 10 5.7 1 0.6
2007 145  13 ND 158 10 6.3 1 0.6
2008 162  58 109 329 12 3.6 3 0.9
2009
(Jan–Jun)
 98  23  88 209 10 4.8 2 1.0
Total 939 115 197 1,251 47 3.8 7 0.6
Abbreviation: ND, not done.
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tients had travelled overseas. Symptoms and their severity 
varied among the patients, ranging from mild colitis to se-
vere PMC. Except for patient 2, none of the patients showed 
high fever (>38.0˚C), increased leukocyte count (>15,000/
μL), increased serum creatinine (>2.0 mg/dL), or decreased 
serum albumin (<2.5 mg/dL). Patient 2 showed high leu-
kocyte count and serum creatinine level due to underlying 
chronic renal failure and an arteriovenous fistula infection. 
Two (patient nos. 2 and 7) cases were diagnosed with su-
spected PMC and PMC by colonoscopic biopsy and con-
sidered probably severe (patient no. 2) or severe (patient no. 
7) according to the criteria proposed by Zar FA et al. [6].
Metronidazole was administered to 4 patients (patient 
nos. 2, 3, 4, and 7) to treat CDI. Because of poor response, 
for patients 4 and 7, the regimen was changed to vancomy-
cin, but the infection recurred. Two patients (patient nos. 1 
and 6) recovered without CDI treatment.
 
DISCUSSION
Although the first case of ribotype 027 infection in Korea 
was reported in 2009 [4], we found that ribotype 027 was 
present in Korea as early as 2006. Since 2006, the prevalence 
of ribotype 027 isolates has been 0.8% (7/870). Except for 
patient no. 6, all the patients had most likely acquired the 
infection in a hospital. We recovered these isolates from 7 
patients who had visited 4 different hospitals located in 
Seoul and Gyeonggi province; this indicated an early stage 
of dissemination to Korean hospitals. Two of these hospitals 
sent the samples to a commercial laboratory for culturing C. 
difficile, and the samples were redirected to the S hospital in 
Seoul where the tests were performed. The presence of ribo-
type 027 in an infant was clinically irrelevant; however, this 
finding suggested that the isolate was easily transmissible. 
 Severe diseases are more likely to be caused by ribotype 
027 strains than by non-027 strains, because the ribotype 
027 strains produces excessive amounts of toxins A and B 
as a result of tcdC deletion [5]. There is no consensus about 
the definition of severe CDI. However, as per the criteria 
proposed by Zar et al. [6], 2 of the 7 cases in this study, like 
the first case reported in Korea [4], were either probably se-
vere (case no. 2) or severe (case no. 7). In North America, 
patients infected with the ribotype 027 isolates had severe 
symptoms more frequently; however, a study in England 
showed no such evidence [13]. 
Mortality due to ribotype 027 infection increases with the 
patient’s age. In a Canadian study, 44.1% of the patients were 
older than 65 yr, and 8.1% of them died within 30 days after 
diagnosis [14]. In our study, 3 out of 7 patients (42.8%) were 
older than 65 yr, and none of them died from CDI.
Anti-tuberculous agents are rarely associated with CDI. 
Among these agents, only rifampin is considered a cause of 
CDIs because rifampin has an antibiotic effect on a wide 
range of bacteria, whereas isoniazid and ethambutol have 
little or no activity against anaerobes [15]. In our study, 4 
patients had received rifampin. 
In our study, 6 of the 7 isolates were resistant to moxiflox-
acin; this was also true for the recent epidemic-causing PCR-
ribotype 027 strains isolated in other countries. In contrast, 
the PCR-ribotype 027 strains isolated prior to 2001 were su-
sceptible to moxifloxacin [5]. 
PFGE patterns of 5 isolates (1, 4, 5, 6, and 7) were identi-
cal. Compared to the pattern of these 5 isolates, the pattern 
for isolates 2 and 3 differed in 3 and 2 bands, respectively 
(Fig. 1). All the isolates were categorized as different MLVA 
types. The VNTR loci used to discriminate these isolates 
were CDR4, CDR9, CD48, CDR49, and CDR60. MLVA 
typing indicated that these isolates were not clones. All the 
7 cases had occurred sporadically. 
For differentiating the isolates, MLVA was more useful 
than PFGE. 
C. difficile ribotype 027 is uncommon, but it has emerged 
in Korea. The spread of this ribotype should be closely mo-
nitored in order to avoid an outbreak of CDI in Korea.
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